Literature DB >> 12923394

Why cardiovascular mortality is higher in treated hypertensives versus subjects of the same age, in the general population.

Athanase Benetos1, Frédérique Thomas, Kathryn E Bean, Louis Guize.   

Abstract

OBJECTIVE: The aim of the present study was to assess whether increased cardiovascular mortality in treated hypertensives could be explained by high blood pressure levels, or by the presence of associated risk factors and/or associated diseases.
DESIGN: The study sample consisted of 8893 treated hypertensive men and women from the Investigations Préventives et Cliniques cohort, and 25880 gender-matched and age-matched untreated subjects from the same cohort. Vital status was obtained for an 8-12 year period.
RESULTS: Treated hypertensive subjects had higher systolic blood pressure (SBP) (+ 15 mmHg) and higher diastolic blood pressure (+ 9 mmHg), and a higher prevalence of associated risk factors and diseases. Treated hypertensives compared with untreated subjects presented a two-fold increase in the risk ratio (RR) for cardiovascular mortality [RR, 1.96; 95% confidence interval (CI), 1.74-2.22] and coronary mortality (RR, 1.99; 95% CI, 1.63-2.44). Adjustment for unmodifiable risk factors decreased the excess cardiovascular risk observed in treated subjects only slightly: RR, 1.77; 95% CI, 1.56-2.00 for cardiovascular mortality; and RR, 1.76; 95% CI, 1.44-2.16 for coronary mortality. After additional adjustment for modifiable associated risk factors, the increased mortality in treated subjects persisted: RR, 1.52; 95% CI, 1.33-1.74 for cardiovascular mortality; and RR, 1.49; 95% CI, 1.19-1.86 for coronary mortality. Only after additional adjustment for SBP were cardiovascular mortality and coronary mortality similar in the two groups of subjects: RR, 1.06; 95% CI, 0.92-1.23; and RR, 1.06; 95% CI, 0.85-1.35, respectively.
CONCLUSIONS: The increased cardiovascular mortality in treated hypertensive subjects as compared with untreated subjects is mainly due to high SBP levels under treatment. This result suggests that the excess risk found in treated hypertensives may be drastically reduced if SBP were brought under control.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12923394     DOI: 10.1097/00004872-200309000-00011

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  20 in total

Review 1.  The benefit of angiotensin AT1 receptor blockers for early treatment of hypertensive patients.

Authors:  Bruno Trimarco; Ciro Santoro; Marco Pepe; Maurizio Galderisi
Journal:  Intern Emerg Med       Date:  2017-08-02       Impact factor: 3.397

Review 2.  Drugs for cardiovascular disease prevention in women: implications of the AHA Guidelines--2007 Update.

Authors:  Nanette K Wenger
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 3.  Primary and secondary prevention of stroke by antihypertensive treatment in clinical trials.

Authors:  Guido Grassi; Francesca Arenare; Fosca Quarti Trevano; Raffaella Dell'Oro; And Giuseppe Mancia
Journal:  Curr Hypertens Rep       Date:  2007-08       Impact factor: 5.369

4.  Biodemography: new approaches to understanding trends and differences in population health and mortality.

Authors:  Eileen Crimmins; Jung Ki Kim; Sarinnapha Vasunilashorn
Journal:  Demography       Date:  2010

Review 5.  Hypertension Survey in Italy: Novel Findings from the Campania Salute Network.

Authors:  Eugenio Stabile; Raffaele Izzo; Francesco Rozza; Maria Angela Losi; Nicola De Luca; Bruno Trimarco
Journal:  High Blood Press Cardiovasc Prev       Date:  2017-07-01

Review 6.  Can we justify goal blood pressure of <140/90 mm Hg in most hypertensives?

Authors:  Raymond R Townsend
Journal:  Curr Hypertens Rep       Date:  2005-08       Impact factor: 5.369

7.  The impact of cardiovascular risk-factor profiles on blood pressure control rates in adults from Canada and the United States.

Authors:  Finlay A McAlister; Cynthia Robitaille; Cathleen Gillespie; Keming Yuan; Deepa P Rao; Steven Grover; Sulan Dai; Helen Johansen; Michel Joffres; Fleetwood Loustalot; Norm Campbell
Journal:  Can J Cardiol       Date:  2013-03-01       Impact factor: 5.223

Review 8.  Antihypertensive treatment and stroke prevention: from recent meta-analyses to the PRoFESS trial.

Authors:  Guido Grassi; Fosca Quarti-Trevano; Raffaella Dell'oro; Giuseppe Mancia
Journal:  Curr Hypertens Rep       Date:  2009-08       Impact factor: 5.369

9.  A Comparison of Biological Risk Factors in Two Populations: The United States and Japan.

Authors:  Eileen M Crimmins; Sarinnapha Vasunilashorn; Jung Ki Kim; Aaron Hagedorn; Yasuhiko Saito
Journal:  Popul Dev Rev       Date:  2008-09-05

Review 10.  The evolution of systolic blood pressure as a strong predictor of cardiovascular risk and the effectiveness of fixed-dose ARB/CCB combinations in lowering levels of this preferential target.

Authors:  Jean-Jacques Mourad
Journal:  Vasc Health Risk Manag       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.